New β-Alanine Derivatives Are Orally Available Glucagon Receptor Antagonists
摘要:
A weak human glucagon receptor antagonist with an IC50 of 7 mu M was initially found by screening of libraries originally targeted to mimic the binding of the glucagon-like peptide (GLP-1) hormone to its receptor. Optimization of this hit for binding affinity for the glucagon receptor led to ligands with affinity in the nanomolar range. In addition to receptor binding, optimization efforts were made to stabilize the molecules against fast metabolic turnover. A potent antagonist of the human human glucagon receptor was obtained that had 17% oral availability in rats with a plasma half-life of 90 min. The major metabolites of this lead were identified and used to further optimize this series with respect to pharmacokinetic properties. This final optimization led to a potent glucagon antagonist that was orally available in rats and dogs and was efficacious in lowering blood glucose levels in a diabetic animal model.
Synthesis, tuberculosis inhibitory activity, and SAR study of N-substituted-phenyl-1,2,3-triazole derivatives
作者:Marilia S. Costa、Núbia Boechat、Érica A. Rangel、Fernando de C. da Silva、Alessandra M.T. de Souza、Carlos R. Rodrigues、Helena C. Castro、Ivan N. Junior、Maria Cristina S. Lourenço、Solange M.S.V. Wardell、Vitor F. Ferreira
DOI:10.1016/j.bmc.2006.08.019
日期:2006.12
The aim of this work was to describe the synthesis, the in vitro anti-Mycobacterium tuberculosis profile, and the structure-activity relationship (SAR) study of new N-substituted-phenyl-1,2,3-triazole-4-carbaldehydes (3a-l). The reactions of aromatic amine hydrochlorides with diazomalonaldehyde (1) produced several N-substituted-phenyl-1,2,3-triazole-4-carbaldehydes (3a-l) in moderate-to-good yields
Original cytotoxic bisindolealkaloids with a 1,2,3,4-tetrahydroquinoline bridge were synthesized by reductive amination with various anilines. The most cytotoxic compounds display a high and dose-dependent cell cycle effect with accumulation in the G1 phase. Influence of substitution of the starting aniline on the reaction and on cytotoxicity of produced dimers was pointed out.
Haloanilino Derivatives of Pyrimidines, Purines, and Purine Nucleoside Analogs: Synthesis and Activity against Human Cytomegalovirus
作者:Maria Medveczky、Te-Fang Yang、Joseph Gambino、Peter Medveczky、George E. Wright
DOI:10.1021/jm00010a026
日期:1995.5
DNA synthesis by human cytomegalovirus (HCMV)-infected human embryonic lung (HEL) cells in culture. In general, active compounds had moderate to low selectivity for viral vs host cell DNA synthesis. Nucleoside and acyclonucleoside analogs of 2-(3,5-dichloroanilino)purines inhibited both HCMV and cellular DNA synthesis at similar concentrations. 2-Amino-4-chloro-6-(3,5-dichloroanilino)pyrimidine and
Verfahren zur Herstellung von m-chlorsubstituierten Anilinen
申请人:BAYER AG
公开号:EP0069907A2
公开(公告)日:1983-01-19
Die Erfindung betrifft ein Verfahren zur Herstellung von m-chlorsubstituierten Anilinen durch selektive Enthalogenierung von höherchlorierten Anilinen in saurem Medium in Gegenwart von Edelmetallkatalysatoren und in Gegenwart von gegebenenfalls substituierten Phenolen.
Die nach dem erfindungsgemäßen Verfahren erhältlichen 3-Chlor- bzw. 3,5-Dichloraniline sind bekannte Zwischenprodukte und können zur Herstellung von Pflanzenschutzmitteln verwendet werden.
Synthesis and Pharmacological Evaluation of <i>N</i>-(2,5-Disubstituted phenyl)-<i>N</i>‘-(3-substituted phenyl)-<i>N</i>‘-methylguanidines As <i>N</i>-Methyl-<scp>d</scp>-aspartate Receptor Ion-Channel Blockers
作者:Lain-Yen Hu、Junqing Guo、Sharad S. Magar、James B. Fischer、Kathleen J. Burke-Howie、Graham J. Durant
DOI:10.1021/jm970459c
日期:1997.12.1
In the mammalian central nervous system, the N-methyl-D-aspartate (NMDA) subclass of glutamate receptors may play an important role in brain diseases such as stroke, brain or spinal cord trauma, epilepsy, and certain neurodegenerative diseases. Compounds which specifically antagonize the actions of the neurotransmitter glutamate at the NMDA receptor ion-channel site offer a novel approach to treating these disorders. CERESTAT (4, aptiganel CNS 1102) is currently undergoing clinical trial for the treatment of traumatic brain injury and stroke. Previously, we reported that analogues of N-1-naphthyl-N'-(3-ethylphenyl)-N'-methylguanidine (4) bound to the NMDA receptor ion-channel site with high potency and selectivity. Recently, molecules active at both a receptors and NMDA receptor sites were investigated. A series of substituted diphenylguanidines 6 which are structurally related to N-1-naphthyl-N'-(3-ethylphenyl)-N'-methylguanidine was prepared. Compounds containing appropriate substitution pattern in one of the phenyl rings of diphenylguanidines displayed high affinity. For example, N-(2,5-dibromophenyl)-N'-(3-ethylphenyl)-N'-methylguanidine (27b, R-2 = R-5 = Br, R-3 = C2H5) exhibited potency at both a receptors and NMDA receptor sites; 27b also showed high efficacy in vivo in a neonatal rat excitotoxicity model. Further studies indicated that substituent effects were important in this compound series, and 2,5-disubstituted phenyl was the preferred substitution pattern for high-affinity binding at NMDA receptor sites. Bromo and methylthio were the optimal substituents for the R-2 and R-5 positions of the 2,5-disubstituted phenyl group, respectively. N-(2-Bromo-5-(methylthio)phenyl)-N'-(3-ethylphenyl)- N'-methylguanidine (34b, R-2 = Br, R-5 = SMe, R-3 = C2H5) was highly active at NMDA receptor sites. We found that the binding affinity of guanidines of type 6 could be further enhanced with the appropriate substitution at R-3. Optimal activity in this series are afforded by 43b and 44b (R-2 = Cl or Br, R-5 = R-3 = SCH3). Both 43b and 44b bound to NMDA receptor sites with high potency and selectivity (K-i vs [H-3]MK-801: 1.87 and 1.65 nM, respectively); these compounds are active in vivo in various animal models of neuroprotection. The structure-activity relationships for-these compounds at the NMDA receptor ion-channel site are discussed.